News Releases

 

BioSante Pharmaceuticals to Present at The BIO International Convention

LINCOLNSHIRE, Illinois (May 14, 2009) – Stephen M. Simes, president and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present at the BIO International Convention in Atlanta, Georgia, on Tuesday, May 19, 2009 at 4:20 pm EDT. The BIO International Convention (BIO) is a symposium including leading pharmaceutical and biotechnology companies presenting to institutional investors, portfolio managers, analysts and the media, to discuss emerging trends in the sector.

Mr. Simes will discuss the LibiGel® (testosterone gel) clinical development plan and recent primary research data indicating the potential size of the U.S. market for BioSante’s LibiGel in the treatment of female sexual dysfunction.

About BIO

The Biotechnology Industry Organization is a trade association that hosts the BIO International Convention. The net proceeds of the event support BIO’s activities throughout the year. BIO is the champion of biotechnology and the advocate for its member organizations – both large and small.

BIO is the world’s largest biotechnology organization, providing advocacy, business development, and communications services for more than 1,200 members worldwide. Corporate members range from entrepreneurial companies in the process of developing a first product to Fortune 100 multinationals. BIO also represents state and regional biotech associations, academic centers, and service providers to the industry.

Since BIO was formed in 1993, the biology-based, entrepreneurial industry has grown from a small number of companies concentrated in a few cities to an industry that increasingly extends throughout society. Nearly every state courts biotechnology development, as do an increasing number of countries around the world.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGelŪ (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.

Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. Under BioSante’s license agreement with Antares Pharma, BioSante is required to pay Antares a portion of the royalties, license and milestone payments received for products covered by that agreement. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.

###

For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220
azachary@harrisdmckinney.com